COMMUNIQUÉS West-GlobeNewswire

uniQure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family Providing Broad Protection of the Hyperactive Padua Variant of Factor IX (FIX-Padua)
19/10/2017
~ Issued Patent in the U.S. Covers Use of FIX-Padua in Gene Therapy ~ ~ Divisional patent applications filed to further strengthen Padua intellectual property position ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, [...]
uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018
19/10/2017
~ AMT-060 with the FIX-Padua Modification (AMT-061) Demonstrates Substantial Increase in FIX Activity in Non-human Primates ~ ~ Plans to Initiate Pivotal Study with Enhanced AMT-061 in 2018 ~ ~ Achieves Alignment with [...]
Conférence de presse du mercredi à l'occasion de la Conférence mondiale sur le cancer du poumon : Progrès PD-1/PD-L1 et interventions pour prévenir et traiter le cancer du poumon
19/10/2017
YOKOHAMA, Japon, 2017-10-19 (GLOBE NEWSWIRE) -- La conférence de presse finale organisée à l'occasion de la 18 e Conférence mondiale sur le cancer du poumon (WCLC) de l'Association internationale pour l'étude du cancer [...]
HOMEVI S.A.S. ISSUES A NOTICE OF CONDITIONAL REDEMPTION OF ITS €608 MILLION 6.875% SENIOR SECURED NOTES DUE 2021 AND ITS €200 MILLION FLOATING RATE SENIOR SECURED NOTES DUE 2021
19/10/2017
Suresnes, October 19, 2017 - 9:00 am CET HomeVi S.A.S. ("HomeVi"), today announces that it has issued a notice of conditional redemption for all of its outstanding €608,000,000 6 7 / 8 % Senior Secured Notes due 2021 ( [...]
Helsinn Announces Attendance at the CPhI 2017 Conference in Frankfurt
19/10/2017
Helsinn Announces Attendance at the CPhI 2017 Conference in Frankfurt Helsinn will be attending between 24-26 October at Booth Number 61B20, Hall 6.1 on the Integrated Pharma Gold corridor Helsinn will introduce its [...]
The Board of Directors of Nexstim Plc resolved on amendments of the stock options 2016 and on a new stock option plan for the CEO
19/10/2017
Company Announcement, Helsinki, 19 October 2017 at 9:00 AM The Board of Directors of Nexstim Plc resolved on amendments of the stock options 2016 and on a new stock option plan for the CEO Stock options 2016 The Board [...]
High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds
19/10/2017
Global survey of 584 caregivers of children, young adults and adults with Dravet illustrates the detrimental effect of debilitating, frequent seizures on quality of life and co-morbidities Results suggest a need for [...]
Nestlé reports nine-month sales for 2017
19/10/2017
This press release is also available in Français (pdf) and Deutsch (pdf) Follow today's event live 14:00 CEST Investor call audio webcast Full details in Events ............. Vevey, October 19, 2017 Nestlé reports nine- [...]
Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee
18/10/2017
Bagsværd, Denmark, 18 October 2017 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0 in favour of the approval [...]
XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
18/10/2017
AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan [...]
Arix Bioscience notes Harpoon Therapeutics' immuno-oncology collaboration with AbbVie
18/10/2017
Arix Bioscience notes Harpoon Therapeutics' immuno-oncology collaboration with AbbVie LONDON, 18 October 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global healthcare and life science company supporting [...]
InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC
18/10/2017
New 3D InSight(TM) Human Liver Fibrosis Model represents a powerful tool for screening efficacy and safety of anti-fibrotic drugs in vitro. Schlieren, Switzerland, Oct. 18, 2017 (GLOBE NEWSWIRE) -- InSphero AG, the [...]
Crown Bioscience partagera son expertise scientifique dans l'évaluation préclinique des molécules expérimentales anticancer lors de la Conférence internationale sur les cibles moléculaires et...
18/10/2017
Crown Bioscience partagera son expertise scientifique dans l'évaluation préclinique des molécules expérimentales anticancer lors de la Conférence internationale sur les cibles moléculaires et les agents thérapeutiques [...]
uniQure Presents New Preclinical Data on AMT-130 in Huntington's Disease at the ESGCT 25th Anniversary Congress in Berlin
18/10/2017
One-time Administration of AMT-130 Demonstrates Survival Benefit and Functional Improvement of Huntington's Disease Symptoms in Preclinical Study IND-enabling Toxicology Study Initiated LEXINGTON, Mass. and AMSTERDAM, [...]
Enzymatica AB: Complete article from COLDPREV I study published - strengthens documentation for ColdZyme
18/10/2017
COLDPREV I Eng 171018 This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
Conférence de presse du mardi de la Conférence mondiale sur le cancer du poumon : des preuves à l'appui des interventions novatrices contre le cancer du poumon
18/10/2017
YOKOHAMA, Japon, le 18 octobre 2017 (GLOBE NEWSWIRE) - La conférence de presse organisée aujourd'hui à l'occasion de la 18 e Conférence mondiale sur le cancer du poumon (World Conference on Lung Cancer - WCLC) de l' [...]
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
18/10/2017
FIT Biotech Oy Company release October 18, 2017 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]
Photocure ASA: FDA grants priority review for Cysview® supplemental New Drug Application (sNDA)
18/10/2017
Oslo, Norway, October 18, Photocure ASA (OSE: PHO) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Cysview ® on a priority review basis. [...]
Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
18/10/2017
Nearly 70% of patients maintained platelet counts of >=30×10 9 /L without rescue therapy for prolonged periods, reducing the overall risk of bleeding More than one-third of patients permanently stopped one or more [...]

Pages